التفاصيل البيبلوغرافية
| العنوان: |
Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes |
| المؤلفون: |
Coleman, Ruth L., Scott, Charles A. B., Lang, Zhihui, Bethel, M. Angelyn, Tuomilehto, Jaakko, Holman, Rury R. |
| المساهمون: |
Clinicum, Department of Public Health |
| بيانات النشر: |
BMC |
| سنة النشر: |
2019 |
| المجموعة: |
Helsingfors Universitet: HELDA – Helsingin yliopiston digitaalinen arkisto |
| مصطلحات موضوعية: |
Impaired glucose tolerance, Type 2 diabetes, Cardiovascular disease, Alpha glucosidase inhibitor, Meta-analysis, DOUBLE-BLIND TRIAL, ACARBOSE, INTERVENTION, PREVENTION, TOLERANCE, PROGRESSION, MORTALITY, MELLITUS, RISK, 3121 General medicine, internal medicine and other clinical medicine |
| الوصف: |
Background Alpha-glucosidase inhibitors (AGIs) have been shown to reduce incident type 2 diabetes but their impact on cardiovascular (CV) disease remains controversial. We sought to identify the overall impact of AGIs with respect to incident type 2 diabetes in individuals with impaired glucose tolerance (IGT), and CV outcomes in those with IGT or type 2 diabetes. Methods We used PubMed and SCOPUS to identify randomized controlled trials reporting the incidence of type 2 diabetes and/or CV outcomes that had compared AGIs with placebo in populations with IGT or type 2 diabetes, with or without established CV disease. Eligible studies were required to have >= 500 participants and/or >= 100 endpoints of interest. Meta-analyses of available trial data were performed using random effects models to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for incident type 2 diabetes and CV outcomes. Results Of ten trials identified, three met our inclusion criteria for incident type 2 diabetes and four were eligible for CV outcomes. The overall HR (95% CI) comparing AGI with placebo for incident type 2 diabetes was 0.77 (0.67-0.88), p <0.0001, and for CV outcomes was 0.98 (0.89-1.10), p = 0.85. There was little to no heterogeneity between studies, with I-2 values of 0.03% (p = 0.43) and 0% (p = 0.79) for the two outcomes respectively. Conclusions Allocation of people with IGT to an AGI significantly reduced their risk of incident type 2 diabetes by 23%, whereas in those with IGT or type 2 diabetes the impact on CV outcomes was neutral. ; Peer reviewed |
| نوع الوثيقة: |
article in journal/newspaper |
| وصف الملف: |
application/pdf |
| اللغة: |
English |
| العلاقة: |
The ACE study was funded by Bayer AG.; Coleman , R L , Scott , C A B , Lang , Z , Bethel , M A , Tuomilehto , J & Holman , R R 2019 , ' Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes ' , Cardiovascular Diabetology , vol. 18 , no. 1 , 135 . https://doi.org/10.1186/s12933-019-0933-yTest; 3b3e15d6-2e01-4258-83f3-e8cef2cf6b0e; http://hdl.handle.net/10138/306833Test; 000490978500001 |
| الإتاحة: |
http://hdl.handle.net/10138/306833Test |
| حقوق: |
cc_by ; openAccess ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: |
edsbas.7520D31E |
| قاعدة البيانات: |
BASE |
